IFNA1 and viral infectious disease: As other viruses, SARS-CoV-2 also antagonizes IFN-induction in infected cells, thereby calling for exogenous IFN-administration as a therapeutic strategy, which is already being exploited for treating diverse virus infections (126, 127).